Breast cancer prognosis
The present invention provides gene expression profiles indicative of whether a patient afflicted with PR driven malignancies is likely to be responsive to treatment with a therapeutic compound that is an anti-progestin. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. Also, provided are methods of using gene expression profiles and assays for identifying the presence of a gene expression profile in a patient.
1. A method of treating breast, ovarian, endometrial or uterine cancer in a patient, said method comprising:
a) obtaining a breast, ovarian, endometrial or uterine cancer sample from said patient;
b) detecting whether expression of THY1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513 is increased in said cancer sample as compared to a control;
c) diagnosing said patient with breast, ovarian, endometrial or uterine cancer amenable to treatment with an anti-progestin, alone or in combination with other treatment when the expression of THY1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513 is increased in said cancer sample as compared to a control; and
d) administering an effective amount of an anti-progestin to said patient with increased expression of THYL1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513.
2. A method of treating breast, ovarian, endometrial or uterine cancer in a patient, said method comprising:
a) obtaining a breast, ovarian, endometrial or uterine cancer sample from said patient;
b) detecting whether expression of THY1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513 is increased in said cancer sample as compared to a control, wherein detection of increased expression is carried out with the use of radiolabeled probes for THY1, KLF9, SPINK5L3, PHLDA1,MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513, wherein said probes comprise SEQ ID NOs: 16-31;
c) diagnosing said patient with breast, ovarian, endometrial or uterine cancer amenable to treatment with an anti-progestin, alone or in combination with other treatment when the expression of THY1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513 is increased in said cancer sample as compared to a control; and
d) administering an effective amount of an anti-progestin-to said patient with increased expression of THY1, KLF9, SPINK5L3, PHLDA1, MAP1A, SPRYD5, ATG12, PDK4, MSX2, TUBA3E, TSC22D1, TUBA3D, KHDRBS3, UTS2D, SLC35C1 and KIAA0513.